Entrectinib in Asian patients with ROS1 fusion-positive non-small cell lung cancer: updated efficacy and safety analysis
This analysis demonstrates continued efficacy of entrectinib in Asian patients with advanced ROS1-fp NSCLC, both overall and in the 1L setting. No new safety signals emerged.
Authors
- Yan Yu (ORCID: https://orcid.org/0000-0002-5478-1733)
- Xiaorong Dong (ORCID: https://orcid.org/0000-0001-7470-1836)
- Pengcheng Zhang (ORCID: https://orcid.org/0000-0002-4546-0022)
- Yun Fan (ORCID: https://orcid.org/0000-0002-0561-0292)
- Yanjun Shi (ORCID: https://orcid.org/0000-0003-2078-2137)
- Jun Zhao (ORCID: https://orcid.org/0000-0002-9460-6796)
- Xichun Hu (ORCID: https://orcid.org/0000-0001-5856-830X)
- Rui Luo (ORCID: https://orcid.org/0000-0002-5202-0236)
- Juan Li (ORCID: https://orcid.org/0000-0002-1617-3294)
- Chia‐Chi Lin (ORCID: https://orcid.org/0009-0006-5084-0819)
- Shun Lu
Institutions
- Harbin Medical University (CN)
- Shanghai Chest Hospital (CN)
- Fudan University Shanghai Cancer Center (CN)
- Zhejiang Cancer Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Sichuan Cancer Hospital (CN)
- Roche (China) (CN)
- Wuhan Union Hospital (CN)
- National Taiwan University Hospital (TW)
- Ministry of Education (ET)
- Union Hospital (CN)
- Hangzhou Cancer Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108851
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00